Biological Implants Market

The global biological implants market size is anticipated to expand at a considerable CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the high prevalence of chronic diseases and changing lifestyle, which increase the need for better and effective drug delivery system.

Biological implants are bioengineered products, administered in living cells in human tissues along with of active ingredients, which are used to cure the disease. They are prepared by biosynthetic materials such as collagen and tissue-engineered products such as tissue and artificial skin. With the emergence of new infectious disease, the medical devices market are witnessing tremendous growth due to the biological implants development.

The biological implants has its wide applications including vascular therapy, cardiology, trauma, dental, spine, orthopedics, and wound care divisions. Some bioactive implants are drug eluting stents, hormonal implants, and implantable drug pumps. The regenerative medicine development in recent time has supported the market growth. This includes a range of therapeutic methodologies such as the use of bio-based materials for treating the principle cause of a disease. Advancements in soft tissue grafts for a many complex methods such as breast reconstruction, thoracic reconstruction, and abdominal wall reconstruction among others causes the decrease in contamination rates of bioprosthetic mesh materials.

The COVID-19 pandemic outbreak has adversely affected the world economy and caused a huge setback in terms of business operations globally. The restriction around the world with nationwide lockdowns as well as travel restriction has impacted the market growth. The early 2020 showed a slowdown in the market growth due to the restriction and rising cases of the pandemic. As the cases started to decline substantially across the globe or at least get under control in several parts of the globe had pushed to accelerate the growth rate of the market.

Market Trends, Drivers, Restraints, and Opportunities

• Inclining research activities in the field with high approval rates of products and large investments by the major player of the market for new product development are boosting the market growth.
• Rising geriatric population is one of the major factors propelling the biological implants market as the old-aged people are more vulnerable to chronic diseases such as endovascular diseases, orthopedic disorders, cardiovascular diseases, and dental disorders.
• Increasing technological advancement in the area of tissue engineering and regenerative medicine is driving the market growth in positive direction.
• Issues concerning around side effects and expensive manufacturing cost are the key challenges that can restrain the market growth during the forecast period.
• Complexity issues around reimbursement policy in various regions acts as a major restraining factor for the market development.
• Highly effective results of biological implants and wide prevalence of chronic diseases across the globe are likely to offer huge opportunities for the market growth during the forecast period.

Scope of Biological Implants Market Report

The report on the global biological implants market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Biological Implants Market Segment Insights

Xenografts segment is expected to grow at a rapid pace

Based on products, the global biological implants market is divided into autografts, allografts, and xenografts. The xenografts segment is expected to grow at a rapid pace during the forecast period due to the development in the area of tissue engineering and vascular engineering for the cure of diseases by the use of xenogeneic vessels such as pig aorta. Xenografts are easily available as well as the procurement process is also easy. There is no issue of morbidity of donors, which is estimated to bolster the segment growth in the near future. Meanwhile, the allografts segment is anticipated to grow at a considerable rate in the coming years owing to its great aesthetic results.

Cardiovascular implants segment is projected to expand at a considerable CAGR

On the basis of applications, the market is classified as cardiovascular implants, orthopaedic implants, and other soft tissue implants. The cardiovascular implants segment is projected to expand at a considerable CAGR during the forecast period. The segment growth is attributed to high cardiovascular disorders due to cholesterol abnormalities and low physical activities. The cardiac tissue implant is extensively adopted for the preparation of allograft valves and heteograft valves, which are collected from bovine pericardial valves & porcine heart as well as stentless valve.

The orthopedic implants segment, however, is expected to exhibit a significant growth pace in the coming years as the cases of orthopedic problems are rising significantly globally over the years. Orthopedics implants consists of orthobiologics, reconstructive joint replacements, and sports medicine. The implants are considered to be showing good results for the patients with problems. This ultimately drives the segment to push for the wide expansion of the segment market share.

Surgical segment is anticipated to demonstrate lucrative growth

Based on the modes of administration, the global biological implants market is bifurcated into surgical and injectable. The surgical implants segment is anticipated to demonstrate lucrative growth in the coming years owing to launching of large number of new products by the major market players and introduction of innovative surgical implanted devices.

On the other hand, the injectable segment is expected to account for a key market share in the future owing to the ease of application as well as tissue biocompatibility of injectable products. Rapid introduction of various minimal invasive technique for the implants presents another key driver of the segment.

North America is anticipated to constitute a major market share

In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to constitute a major market share during the projected period owing to the wide development of highly advanced technologies in the region along with the availability of adequate number of skilled professionals. Wide incidence of chronic diseases in the region and extensive programs for public awareness about the implants among the population are key drivers of the regional market growth.

The Asia Pacific market is estimated in to grow at substantial pace during the forecast period owing to the presence of large untapped population in the region and favorable government initiatives for implant market. The rise in research activities in the region is also a key factor driving the market growth in the region.

Segments

The global biological implants market has been segmented on the basis of

Products

• Autografts
• Allografts
• Xenografts

Applications

• Cardiovascular Implants
• Orthopaedic Implants
• Other Soft Tissue Implants

Mode of Administration

• Surgical
• Injectables

Regions

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

Key Players

• Allergan Plc
• Maxigen Biotech Inc.
• Integra LifeSciences Corp.
• Edwards LifeSciences Corp.
• Stryker Corp.
• Acelity
• Medtronic
• NuVasive, Inc.
• RTI Surgical
• BioPolymer GmbH & Co. KG
• Baxter International
• Vericel
• Aplhatec Spine Inc.
• CryoLife
• Conmed Corp.
• Biotissue Technologies
• Auto Tissue Berlin GmbH
• MiMedx Group, Inc.
• Organogenesis Inc.
• IOP Ophthalmics
• Osiris Therapeutics

Competitive Landscape

Key players competing in the global biological implants market are Allergan Plc; Maxigen Biotech Inc.; Integra LifeSciences Corp.; Edwards LifeSciences Corp; Stryker Corp.; Acelity; Medtronic; NuVasive, Inc.; RTI Surgical; BioPolymer GmbH & Co. KG; Baxter International; Vericel; Aplhatec Spine Inc.; CryoLife; Conmed Corp.; Biotissue Technologies; Auto Tissue Berlin GmbH; MiMedx Group, Inc.; Organogenesis Inc.; IOP Ophthalmics; and Osiris Therapeutics.